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UNCOUPLING PROTEIN 2 EXPRESSION AND ITS ASSOCIATION WITH 
ATHEROSCLEROTIC DISEASE SEVERITY. John K. Forrest, J. Dawn Abbott, Kerry S. 
Russell, and Raymond R. Russell. Section of Cardiology, Department of Internal Medicine, Yale 
University, School of Medicine, New Haven, CT. 
Uncoupling proteins (UCPs) are inner mitochondrial membrane channels that dissipate the proton 
gradient generated by the respiratory chain, and have been shown to play an important role in 
attenuating reactive oxygen species (ROS) generation. Animal studies suggest that changes in 
UCP expression in circulating monocytes may effect atherogenesis by regulating the production 
of ROS known to cause endothelial damage. However, the association between mononuclear cell 
UCP expression in humans and coronary artery disease has not been assessed. The purpose of 
this study was to investigate the association between mononuclear cell uncoupling protein 2 
(UCP2) expression and the severity of coronary artery disease in patients undergoing coronary 
angiography. Peripheral blood samples were obtained from 103 enrolled patients undergoing 
coronary angiography. Coronary atherosclerotic disease burden was assessed using a 15 segment 
stenosis scoring system. Messenger RNA was isolated from the peripheral mononuclear cells and 
real-time PCR was performed to evaluate UCP2 expression. In patients with severe coronary 
artery disease (stenosis score >25) there was a 35% decrease (p<0.02) in monocyte UCP2 mRNA 
expression compared to patients with no to mild coronary artery disease (stenosis score 0-10). 
There was no significant difference in the monocyte expression of UCP2 mRNA in patients with 
moderate disease (stenosis score 11-25) compared to patients with no to mild coronary artery 
disease. This study demonstrates that decreased monocyte UCP2 expression correlates with 
increased atherosclerotic disease burden in patients, and supports the hypothesis that changes in 
monocyte UCP2 expression may modulate vascular oxidant stress and play a role in 
atherogenesis. 
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INTRODUCTION 
Atherosclerosis is the leading cause of morbidity and mortality in Western society 
accounting for more deaths than all types of cancers combined (1). In 2000, there were 946,000 
deaths in the United States that were attributed to cardiovascular disease, the primary 
manifestation of atherosclerosis (2). Although initially thought of simply as a lipid storage 
disease, atherosclerosis is now recognized to be a form of chronic inflammation, characterized by 
the progressive deposition of lipids and fibrous elements in large- and medium-sized arteries (1, 
3-5). This inflammation, resulting from the interactions between lipoproteins, monocyte-derived 
macrophages, T cells, and native cellular elements of the arterial wall, leads to the proliferation of 
a variety of cell types which progressively narrow the lumen of blood vessels, impeding blood 
flow. The manifestations that result include angina from stenosis of coronary arteries, stroke 
from stenosis of the arteries of the cerebrovascular system, and claudication from stenosis of 
arteries in the peripheral circulation. 
Epidemiology and risk factors 
Epidemiological studies over the past 25 years have demonstrated that the development 
of atherosclerotic disease is multifactorial with both genetic and environmental components. 
While some risk factors such as cigarette smoking are preventable and can be modified, many of 
the other proposed contributors to the development of atherosclerotic disease are not completely 
understood. 
Age 
In the clinical setting, one of the most important factors for determining the relative risk 
of atherosclerotic disease is age. For men living in the United States, the relative risk of 
developing cardiovascular disease is seven times greater for a 60-64-year-old than it is for a 30- 
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34-year-old; 21% versus 3% (6). The significant impact age has in risk assessment is evident in 
the components of the Framingham Heart Study’s point system, formulated to predict the 10-year 
risk for developing cardiovascular disease. In this 14-point scoring system, up to 7 points can be 
attributed to age alone. 
Gender 
Another risk factor that is not subject to modification, but has been shown to contribute 
significantly to increased risk of cardiovascular disease is gender. Investigation into the reason 
for this initially focused on estrogens and their “protective” effects, based on the fact that the 
incidence of cardiovascular disease increases substantially in women after menopause. However, 
recent studies have demonstrated that estrogen supplementation may actually increase the risk of 
cardiovascular disease in postmenopausal women (7), although these studies may suffer from 
methodologic problems. Other explanations for the difference in the incidence of atherosclerotic 
disease between men and women suggest that women are protected due to the fact that women 
have, on average, a higher concentration of high-density lipoproteins than men (1). However, 
even when such factors are accounted for, multiple studies have shown that men have a greater 
risk of developing heart disease than do age-matched premenopausal women (8). 
Cigarette Smoking 
While having been promoted early in the last century as a practice supported by 
physicians, as depicted in the Fatima Cigarette advertisement published in the August 11, 1930 
edition of Time Magazine whose caption reads: ‘The old doctor handed over to his doctor son a 
family tradition of high ideals and devoted service. And another tradition has survived, too . . . 
Fatima Cigarettes’, and even suggested as being helpful for those students writing their thesis (see 
figure 1), cigarette smoking has long been known to increase the incidence of coronary artery 
disease (9-11). 
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More recent data, including the 
Surgeon General’s report, estimates that 
smoking may increase atherosclerotic disease 
and the risk of heart attack by as much as 50% 
(12). Of interest is the fact that the risk of 
myocardial infarction in ex-smokers 
approaches that of non-smokers just 2 years 
after smoking cessation (13). 
Figure 1. Early 20th Century Ad. 
Smoking advertisement from the Pennsylvania 
Gazette, April 5th, 1913, showing a graduate 
student writing his thesis. The caption 
underneath reads: ‘Strenuous work, old man, 
but that pure, wholesome Fatima will help’. 
for 
“Diatinciivefy ] 3^ 
JndtYjduaJ' 
Hypertension 
Defined as a systolic pressure >140 mm Hg or a diastolic pressure >90 mm Hg, 
hypertension affects more than 75% of people over the age of 75 (14). These individuals are at 
increased risk for the development of cardiovascular disease and studies have shown that there is 
a linear relationship between increased blood pressure and the incidence of atherosclerotic disease 
(15). As with smoking, multiple studies have revealed that the treatment of hypertension 
dramatically reduces the risk of coronary heart disease and myocardial infarction. These studies 
have shown that successful treatment of hypertension results in a 24-3 1% reduction in the five- 
year risk of developing symptomatic coronary heart disease (16-19). 
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Serum Cholesterol 
The association between low-density lipoprotein (LDL) concentration and atherosclerosis 
is most evident in patients with the autosomal dominant disorder familial hypercholesterolemia. 
This disorder, which is caused by a defective LDL receptor, leads to a 2- to 5-fold elevation in 
LDL concentrations in heterozygous individuals, and a 4- to 6-fold increase in LDL 
concentrations in homozygous individuals. By the age of 15, a remarkable 85% of homozygotic 
patients will have suffered a heart attack; in heterozygotic patients the age at which 85% of 
individuals will have had a myocardial infarction is 60 years (20). However, the LDL 
concentration need not be elevated so dramatically to have a significant effect on atherosclerotic 
disease, as there is a linear relationship between LDL concentration and atherosclerosis for all 
levels of LDL. 
As opposed to LDL, for which there is a positive association between serum 
concentrations and atherosclerosis, the relationship between high-density lipoprotein (HDL) 
concentrations and atherosclerosis is inverse (21). Thus while increased LDL concentrations, as 
seen in familial hypercholesterolemia, lead to early atherosclerosis, the absence of HDL 
cholesterol can also lead to early atherosclerosis, as is seen in some families with Tangier disease, 
an autosomal recessive disorder characterized by the absence of HDL cholesterol due to a defect 
in the ATP binding cassette transport-1 protein (22-26). Newer pharmacological therapies have 
focused on the role of HDL cholesterol by attempting to not only lower LDL, but also raise HDL 
concentrations. 
Diabetes 
Now considered to be an epidemic in the United States, diabetes affects 6.2% of the 
American population (approximately 17 million people) (27). For these patients, the risk of 
developing coronary artery disease is three to five times greater than the general population (28). 
While other confounding conditions, including hypertension and hyperlipidemia are more 
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prevalent in patients suffering from diabetes than in the general population, it has been shown that 
no more than 25% of the excess coronary atherosclerosis risk from diabetes can the attributed to 
these other risk factors (28-30). 
Family History 
The critical importance of obtaining a complete history from each patient is demonstrated 
by studies that have shown that coronary artery disease, when it has occurred before the age of 60 
in first degree relatives, is a strong independent risk factor for cardiovascular events (31, 32). 
While often associated as a risk factor in patients who already are at increased risk for the 
development of coronary artery disease, it is important to recognize that even within low- and 
intermediate risk groups, individuals with a family history of premature coronary artery disease 
have a significantly higher relative risk than individuals without a positive family history (31). 
When compared with men with no parental history of myocardial infarction (MI), patients with a 
history of maternal MI only, paternal MI only, and both maternal and paternal history of MI have 
a relative risk of 1.71, 1.40, and 1.85 respectively. Among women, the respective relative risks 
are 1.46, 1.15, and 2.05 (33). 
C-Reactive Protein 
Recent studies have demonstrated that there is a linear relationship between serum 
concentrations of the inflammatory marker C-reactive protein (CRP) and the risk of myocardial 
infarction or death from coronary causes. Additionally, CRP concentrations have been shown to 
correlate inversely with the progression of angiographically documented coronary atherosclerotic 
disease when patients are treated with statins, independent of change in LDL concentrations (34, 
35). Other markers of inflammation, including homocysteine, have also been implicated as 
independent risk factors for the development of coronary heart disease (36), and the investigation 
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into the molecular mechanisms behind these relationships has offered new insights into the 
pathogenesis of atherosclerosis and the important role that inflammation plays in this process. 
Theories of Pathogenesis of Atherosclerosis 
In humans, the first lesions of atherosclerosis begin with the formation of the ‘fatty 
streak’, which can usually be seen in the aorta as early as the first decade of life, in the coronary 
arteries in the second decade, and in the cerebral artenes by the third or fourth decade (4). While 
not clinically relevant, fatty streaks represent the foundation upon which atherosclerotic lesions 
will continue to develop. The fatty streak occurs as the result of an increase in the concentration 
of lipoproteins within the intimal layer of the arterial vessel wall. There are several proposed 
mechanisms to explain this accumulation of lipoproteins, and while they are similar in many 
aspects, they each emphasize different concepts as the necessary and sufficient events to support 
the development of atherosclerotic lesions. 
Response to Injury Model 
The first proposed theories on the ‘atheromatous effection of arteries,’ date back to the 
1850s, and include Rokitansky’s “incrustation” hypothesis, and Virchow’s “lipid transudation” 
hypothesis. While remarkable in that they were correct in identifying that fibrin deposition and 
modified lipid complexes caused atherosclerosis, these first theories saw the disease as involving 
passive deposition rather than active inflammation (37, 38). The recognition that there was an 
inflammatory component to atherosclerosis was not suggested until over 100 years later when 
Ducan discovered that “injury to the endothelium causes insudation of inflammatory fluid from 
the plasma into the intima followed by degeneration and proliferation” (39). This response-to- 
injury hypothesis was modified and expanded upon by Ross and Glomset who suggested that 
“local injury to the endothelium increases the concentration of plasma proteins in the vicinity of 
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medial smooth muscle cells, and in response to some of these proteins, the cells migrate into the 
intima and proliferate” (40-42). 
This initial response-to-injury theory, however, suggested that direct and continued 
disruption or desquamation of the endothelium was the principal step necessary for atheromatous 
formation and progression. More recent studies have demonstrated that the endothelium covering 
atherosclerotic plaques is often completely intact, and thus the hypothesis has been modified to 
suggest that endothelial dysfunction alone is sufficient to initiate atherogenesis through increased 
permeability to atherogenic lipoproteins (1,43). However, other studies have shown that 
increased endothelial permeability to atherogenic lipoprotein alone does not fully explain 
atherosclerotic plaque formation. The reason for this is that in the normal artery, the rate of LDL 
entry is often greater than the rate of LDL accumulation, suggesting that endothelial dysfunction 
is not required for LDL entry into the arterial wall (44). Furthermore, histologic examination of 
coronary arteries has shown that atherogenesis does not occur uniformly throughout the vessel, 
but rather at specific predisposed regions (45, 46). Because LDL entry through the endothelium 
is relatively homogeneous throughout the vessel, it is possible that atherogenic lipoprotein entry 
into the arterial wall may not depend on endothelial injury or dysfunction. Given this, two 
additional models have been proposed that are currently under active investigation. These are 
referred to as the response-to-retention model and the oxidative modification model (1). 
Response to Retention Model 
This hypothesis, first proposed by Williams and Tabas (47), suggestes that lipoprotein 
retention within the arterial wall is the event necessary for atherosclerotic plaque formation. This 
retention is proposed to be facilitated by Apolipoprotein B-100, the only protein associated with 
LDL, which is retained within the arterial wall in close association with arterial proteoglycans (1, 
48, 49). Studies investigating the retention of apoplipoprotein B-containing liproproteins have 
demonstrated that the binding of these molecules to proteogycans is important in the early stages 
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of atherogenesis (50). Once retained within the arterial wall, LDL can form micoaggregates, 
which are actively taken up by macrophages and smooth muscle cells, resulting in foam cell 
formation and thus initiating atherosclerotic plaque formation (51, 52). 
The Oxidative Modification Model 
The oxidative modification hypothesis focuses on the singular importance of LDL in 
atherogenesis, but is unique in that it suggests that LDL in its native state in not atherogenic, and 
that chemical modifications are necessary for LDL particles to be taken up by macrophages in the 
initiating phase of atherosclerosis. The recognition that uptake of LDL by macrophages requires 
that the LDL particle be chemically altered before it can be internalized by macrophages via a 
“scavenger receptor” pathway was first made by Goldstein et al. in 1979 (53). Since then, it has 
been determined that these LDL modifications include oxidation and nonenzymatic glycation. 
Nonenzymatic glycation of apolipoproteins and other arterial vessel wall proteins has been shown 
to occur in diabetic patients with sustained hyperglycemia, one of the factors which may 
contribute to the increased incidence of coronary disease in this population. The role of oxidative 
modification is more clearly understood than the role of nonenzymatic glycation, as oxidation of 
LDL converts the previously non-atherogemc LDL particle into one capable of uptake by 
macrophages (figure 2). Upon LDL oxidation, apolipoprotein B-100 (apo B) undergoes a 
chemical modification whereby it increases the net negative charge of the LDL particle (54). 
This increase in negative charge enables macrophages to internalize the LDL particle via a 
number of scavenger receptor pathways (55). These LDL-containing macrophages become 
cholesterol ester-rich foam cells, forming the Tatty streak’ and the beginning of atherosclerotic 
plaque formation. 
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Figure 2. Oxidative modification hypothesis of atherosclerosis. 
LDL becomes entrapped in the subendothelial space where it is subject to oxidative modification 
by resident vascular cells such as smooth muscle cells, endothelial cells, and macrophages. 
Oxidized LDL stimulates monocyte chemotaxis (A), prevents monocyte egress (B), and supports 
foam cell formation (C). Once formed, oxidized LDL also results in endothelial dysfunction and 
injury (D), and foam cells become necrotic due to the accumulation of oxidized LDL (E). Figure 
from Diaz et. al (56). 
Other atherogenic processes are also initiated in the aftermath of LDL oxidation, and not 
all of these require changes to apo B. For example, it has been shown that during the initial 
stages of in vitro LDL oxidation, “minimally” modified LDL (mmLDL) without altered apo B, is 
capable of recruiting inflammatory cells via the induction of monocyte chemotactic protein-1 
synthesis in smooth muscle and endothelial cells (57-59). Mice lacking the receptor for 
monocyte chemotactic protein-1 are resistant to atherosclerosis (60, 61). With more extensive 
oxidation, the apo B component is fragmented and lysine residues are covalently modified, which 
results in the direct recruitment of monocytes (62) and T lymphocytes (63) due in part to the 
formation of lysophosphatidylcholine (64). This recruitment of inflammatory monocytes and T 
cells further contributes to the continued oxidation of LDL, thus setting the stage for the 
progression of the atherosclerotic lesion. In addition to producing these chemotactic factors, the 

10 
oxidation of LDL also promotes the proliferation of smooth muscle cells (65), the production of 
autoantibodies (66, 67), and the formation of immune complexes that further promote the uptake 
of LDL into macrophages (68, 69). Together these processes form the events necessary for the 
initiation and progression of atherosclerosis. 
While each of these three hypothesis (the respose-to-injury, the response-to-retention, and 
the oxidative modification model) recognizes that LDL is the primary factor involved in the 
initiation and progression of atherosclerosis, and that a humoral inflammatory response is critical 
for the progression of the disease, the oxidative modification hypothesis is unique in its emphasis 
of the importance of oxidative events in initiating atherogenesis. In order to better understand the 
oxidative modification model and the impact that it may have on our understanding of 
atherosclerosis, it is important that we examine the factors that influence LDL oxidation. By 
doing so, we may be able to elucidate the mechanisms by which LDL oxidation is regulated, 
which could potentially enable us both to better predict the progression of atherosclerotic disease, 
as well as direct pharmacologic or gene based therapies to alter this process. 
What Controls LDL Oxidation? 
There are many oxidants that have been shown in the laboratory to have the potential to 
form reactive oxygen species (ROS) or reactive nitrogen species (RNS). These two products 
have been shown to play important roles in LDL oxidation, and their in vivo production results 
from a variety of cellular and extracellular sources as well as from the utilization of both 
enzymatic and nonenzymatic pathways. The sources of these oxidants are reviewed in detail by 
Stocker and Keaney (1), and include NAD(P)H oxidases, xanthine oxidase, nitric oxide synthase 
(NOS) enzymes, myeloperoxidase, lipoxygenases, free transition metals including iron and 
copper, lipid peroxyl radicals, and the superoxide anion radical (02~-) produced as a by-product 
of electron flow through the mitochondrial electron transport chain. The work presented in this 
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thesis builds upon the importance of ROS generated by monocyte mitochondria, and potential 
regulatory factors in this process. 
There is growing evidence that ROS production via mitochondrial respiration may play 
an important role in inflammation, and that increases in mitochondrial membrane potential can 
enhance mitochondrial superoxide generation (70-73). Work in this area has also suggested that 
uncoupling proteins (UCPs), as a result of their ability to regulate proton leakage through the 
inner mitochondrial membrane, may be key regulators of mitochondrial ROS production (70, 74- 
76). 
Uncoupling Proteins 
Mitochondrial uncoupling proteins are members of the mitochondrial anion carrier 
superfamily that includes UCP1, UCP2 and UCP3. UCPs are integral mitochondrial membrane 
proteins with a tripartite structure consisting of 6 a-helical regions spanning the lipid bilayer with 
both the amino and carboxyl termini on the cytosolic side, and long hydrophilic loops on the 
mitochondrial matrix side. UCPs function to dissipate the electrochemical proton (H+) gradient 
generated by mitochondrial respiration which drives ATP production via the F0FrATPase. UCP- 
1, originally named thermogemn, was discovered in 1976 from functional studies of brown 
adipose tissue mitochondria and was one of the earliest membrane proteins to be sequenced. 
UCP1 was originally thought to be a unique protein found only in mammalian brown adipose 
tissue, but over the past 30 years further research has found five other uncoupling proteins in 
humans, and another one that is found in plants. 
UCP1 is found exclusively in brown adipose tissue and is involved in non-shivering 
thermogenesis. It was cloned in the orthodox manner in that the physiological phenomena of 
non-shivering thermogenesis was first identified, then a cellular explanation was discovered 
(uncoupled mitochondria in brown adipose tissue), then a responsible protein was identified 
(UCP1), and lastly the mRNA corresponding to the protein was sequenced (77). Conversely, 
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UCP2 and UCP3 were identified using “reverse cloning”, they were identified from databases of 
expressed sequence tags or from cDNA libraries as a result of their similarity to UCP1. As a 
result, the functions of UCP2 and UCP3 were unknown at the time of their identification in 1997. 
Since then, there has been considerable research aimed at identifying the role of these proteins, 
although a consensus has not yet been reached. It is clear from the levels of expression of UCP2 
and UCP3 that the heat produced by their uncoupling would not be physiologically significant. 
Based in part on this finding, it is believed that the functions of UCP2 and UCP3 are not the same 
as UCP1. 
Since their identification 7 years ago, there have been several functional roles suggested 
for UCP2 and UCP3. Multiple studies have demonstrated that UCP3 mRNA is found almost 
exclusively in brown adipose tissue and skeletal muscle (78-81). Given this distribution, it has 
been suggested that UCP3 is associated with energy metabolism and regulation of the metabolic 
rate. In a study of Pima Indians, it was found that a polymorphism within the proximal promoter 
region of UCP3 is associated with an increased resting metabolic rate which predisposes affected 
individuals to having a lower total body weight (82). 
UCP2 on the other hand, has been shown to be present throughout the body including in 
the spleen, liver, skeletal muscle, heart, brain, and peripheral mononuclear cells (77). As a result, 
there have been numerous suggested roles for UCP2 (77). These include the regulation of 
mitochondrial ATP synthesis, regulation of fatty acid metabolism, and regulation of ROS 
production and ROS detoxification. 
This work focuses on the proposed roles that UCP2 plays in the regulation and 
production of ROS, and the relevance that this has in the development of atherosclerosis from the 
perspective of the oxidative modification model for atherogenesis. 
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UCP2 and Reactive Oxygen Species 
The superoxide radical (Of-), which serves as the primary precursor to mitochondrial 
H202 generation, is produced largely as a natural by-product of mitochondrial respiration. The 
ability of UCP2 to regulate the production of H202 was first shown by Negre-Salvayre et al. who 
found that GDP was able to raise membrane potential and H202 production of mitochondria from 
nonparenchymal cells expressing UCP2, but was unable to do so in hepatocytes devoid of UCP2 
(74). Further work investigating the relationship between UCP2 and ROS production 
demonstrated that macrophages from UCP2-/- knockout mice have greater superoxide and ROS 
production than wild type animals (83). Additionally, higher levels of ROS have been shown to 
be present in mice deficient for UCP3 (79). 
While first hypothesized in 1997 (74), the correlation between the regulation of 
mitochondrial ROS production by UCP2 and the oxidation of LDL leading to the progression of 
atherosclerotic disease was not demonstrated experimentally until 6 years later when Blanc et al. 
demonstrated that UCP2 plays a protective role in the development of atherosclerosis (84). Their 
experiments demonstrated that when irradiated low-density lipoprotein receptor-deficient (LDLR- 
/-) mice received a bone marrow transplant from either wild-type or UCP2-/- donor mice and 
were subsequently fed an atherogenic diet, there was a significant difference in both plaque size 
and plaque composition depending on the genotype of the donor mouse. Specifically, in LDLR-/- 
mice that received bone marrow transplants from UCP2-/- mice there was a 42% increase in 
atherosclerotic plaque size in the aortic sinus, and a 93% increase in the percentage of plaque 
surface in the thoracic aorta as compared to mice receiving marrow from UCP2+/+ mice (84). 
These experiments emphasize the importance of UCP expression in marrow derived hematologic 
cells in regulating atherogenesis. 
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UCP and Atherosclerosis 
Further investigations into the mechanisms behind this proposed inverse relationship 
between UCP expression and atherosclerotic disease progression have suggested that not only 
does increased UCP expression result in decreased ROS production (74, 79), but also that UCPs 
can inhibit monocyte transendothelial migration, thereby inhibiting the accumulation of 
monocytes/macrophages in an atheromatous lesion (85). Work by Ryu et al. demonstrated that 
the decreased ROS production that occurs as a result of monocyte UCP2 overexpression resulted 
in less monocyte Ca influx, which subsequently lowered monocyte expression of the B-integrin, 
CD11 b, by 75 to 80%. CD1 lb is a regulator of monocyte recruitment and adhesion to endothelial 
cells, and by decreasing its surface expression by overexpressing UCP2, Ryu et al. found that 
there was an inhibition of (32 integrin-dependent adhesion of the monocytes to endothelial cells 
(85). Ryu et al. went on to demonstrate that overexpression of UCP2 in monocytes also inhibited 
the migration of monocytes across cultured endothelial cells in response to monocyte 
chemoattractant protein-1. 
Taken together these findings suggest that, through its ability to decrease ROS 
production, UCP2 may both inhibit the oxidation of LDL, critical for the progression of 
atherosclerosis as detailed in the oxidative model, and also prevent the recruitment and migration 
of monocytes across the endothelium. 
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PURPOSE 
To determine if there is an association between mononuclear cell UCP2 expression and 
the severity of coronary artery disease in patients undergoing cardiac cathetenzation. 
HYPOTHESES 
Decreased UCP2 expression in mononuclear cells results in increased reactive oxygen 
species production, and thus increases LDL oxidation, resulting in more severe coronary artery 
disease. Conversely, increased UCP2 expression in mononuclear cells provides less opportunity 
for LDL modification, and thus confers greater resistance to atherosclerotic plaque formation. 
SPECIFIC AIMS 
1. To obtain patient whole blood samples, isolate peripheral mononuclear cells, and purify 
mRNA. 
2. To develop and validate an assay to measure monocyte UCP2 mRNA expression. 
3. To analyze patient coronary angiograms. 
4. To perform statistical analysis to determine the relationship between monocyte UCP2 
expression and the severity of coronary artery disease as measured by the stenosis score. 
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METHODS 
The author of this thesis participated in all aspects of the design of the study, recruitment 
of patients, collection of patient data, collection and preparation of blood samples, performance of 
real time-RT-PCR analysis, review of coronary angiograms, and data analysis. The following 
groups and individuals contributed to the conduct of the studies: attending invasive cardiologists 
of Yale University School of Medicine and Yale-New Haven Hospital (performed the coronary 
angiography), and J. Dawn Abbott, MD, Kerry Strong Russell, MD, PhD and Raymond Russell, 
MD, PhD (reviewed the coronary angiograms in a blinded fashion, the author was present for all 
of the angiogram reviews). All aspects of the investigation were supervised by Raymond Russell, 
MD, PhD. 
1. Patient Selection 
All patients older than 17 years of age who were referred to the Yale-New Haven 
Hospital Cardiac Catheterization Laboratory for diagnostic cardiac catheterization were eligible 
for the study. Exclusion criteria included the inability to give informed consent, self-reported 
blood transfusion within the previous 14 days of the procedure, history of heart transplantation, 
self-reported acute inflammatory/febrile illness, self-reported autoimmune disease, self-reported 
acute bacteria or viral infection within the previous 14 days, self-reported chronic infections (e.g., 
chronic hepatitis, HIV), self-reported autoimmune disorders, symptomatic anemia, treatment with 
immunomodulatory agents, or use of thyroid hormone replacement agents, which are known to 
affect UCP expression. Patients were approached to request participation in the study prior to the 
time of their cardiac catheterization. This occurred on the outpatient unit, on the medical wards, 
and in the catheterization laboratories of Yale-New Haven Hospital. Patients were given ample 
time to read and have the protocol explained to them as well as to ask questions. The protocol 
was approved by the Human Investigation Committee of the Yale University School of Medicine. 
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2. Collection of Patient Information 
Patient information including age, sex, race, height, weight, current medications, 
allergies, smoking history, family history of heart disease, history of diabetes, history of previous 
coronary revascularization, and history of congestive heart failure where gathered by direct 
patient questioning and review of the patients’ medical record. Laboratory data including serum 
glucose and creatinine concentrations, lipid profile, complete blood count and left ventricular 
ejection fraction, when available, were recorded. (See Appendix 1 for sample patient information 
sheet). 
3. Collection of Patient Blood Samples 
During the catheterization procedure, blood was collected prior to angiography via the 
peripheral arterial sheath that was placed as part of the cardiac catheterization. The blood was 
then distributed into 4 tubes: 10ml each into 2 heparin coated tubes, 9ml into a tube containing 
SST® Gel and Clot Activator for serum isolation, and 9ml into a tube containing 3.2% buffered 
sodium citrate for plasma isolation. The samples were kept at 4°C for between 1 and 4 hours 
before being processed in the laboratory. 
4. Acquisition and Analysis of Coronary Angiograms 
Coronary angiography was performed using standard techniques. Coronary artery 
angiograms were either digitally acquired and stored on the Yale-New Haven Hospital Cardiac 
Catheterization Laboratory server, or recorded onto film, depending on the catheterization lab in 
which the procedure was performed. 
Angiograms were review by three board certified cardiologists (J. Dawn Abbott, MD, 
Kerry Strong Russell, MD, PhD and Raymond Russell, MD, PhD) experienced at reading 
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coronary angiograms who were blinded to the patient’s clinical and biochemical information. The 
burden of coronary atherosclerotic disease was assessed by the stenosis score described by 
Sullivan et al. (86). In this method, the coronary arteries are divided into 15 segments and each 
segment is scored visually using a 0-4 scale for the presence of stenosis (0: no stenosis, 1: <25% 
stenosis, 2: 25-50% stenosis, 3: 51-75% stenosis, 4: >75% stenosis). The stenosis score is then 
calculated as the sum of the scores for each of the 15 segments. (See Appendix 2 for sample 
stenosis scoring sheet). 
5. Isolation of Peripheral Blood Mononuclear Cells 
Mononuclear cells were isolated using Sigma Diagnostics Accuspin_tubes following the 
protocol that accompanied the tubes. First, Histopaque-1077 was brought to room temperature 
and 15 ml of Histopaque-1077 was pipetted into the upper chamber of the Accuspin tube. The 
tube was then centrifuged for 30 seconds at room temperature, after which time the Histopaque 
was displaced into the chamber below the “frit”. Blood from both of the heparin coated tubes 
(20ml total) was then poured into the upper chamber of the Accuspin Tube. Ten milliliters of 
sterile phosphate buffered saline (PBS) was combined with the blood. The tube was then 
centrifuged at 800 x g and 18-26°C for 15 minutes. After centrifugation, the yellow plasma layer 
was aspirated with a 25 ml pipet to within 0.5 cm of the opaque “buffy coat” containing 
mononuclear cells, and the plasma was discarded. The “buffy coat” was then transferred into a 
50 ml conical tube using a PI 000 pipette whose tip had been cut off to prevent unnecessary 
trauma to the cells. The mononuclear cells were then washed by adding 10 ml of isotonic PBS 
and resuspending the cells in the PBS with a 25 ml pipette. The sample was then centrifuged at 
250 x g at 18-26°C for 10 minutes, and then washed again and centrifuged as above. The cells 
were then resuspended in 1 ml of PBS and divided into 500 pi aliquots that were places in 1,5-ml 
microfuge tubes. These tubes were then spun at 5000 rpm in a microfuge at room temperature for 
5 minutes. The supernatant was then aspirated off and the microfuge tubes containing the cell 
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pellets were inverted on drying paper for 2 minutes. To one tube, 300 pi of freezing media was 
added, the cells were resuspended, and the sample stored at -80 °C to cryopreserve cells for 
functional studies and DNA analysis that are to be performed at a later date. To the other 
microfuge tube, 600 pi of RLT buffer (Qiagen) was added to the cells in preparation for RNA 
isolation. 
6. RNA Isolation from Peripheral Blood Mononuclear Cells 
Messenger RNA was isolated from peripheral blood mononuclear cells using Qiaqen 
RNeasy kits. After resuspension in 600 pi of RLT buffer, the cells were homogenized by 
carefully passing the lysate 8 times through a 20-gauge needle fitted to an RNase-free syringe. 
Ethanol (70%, 600 pi) was then added to the homogenized lysate and mixed by pipetting. Six 
hundred microliters of this sample, including any precipitate that had formed, was then added to 
an RNeasy mini column placed inside a 2-ml collection tube. The tube was closed and 
centrifuged for 15 sec at 8000 x g. 
The flow-through from the RNeasy mini column was discarded, and the remaining 
sample was loaded onto the same RNeasy column and centrifuged as before. After 
centrifugation, the flow-through was discarded and 350 pi of buffer RW1 was added to the 
RNeasy mini column containing the sample, and centrifuged for 15 seconds at 8000 x g. The 
flow-through was discarded and on-column DNase digestion was performed using Qiagen 
RNase-free DNase Set to remove any genomic DNA that could interfere with subsequent 
quantification of the mRNA. Per the product protocol, 80 pi of DNase I incubation mix 
(containing 10 pi DNase 1 stock solution and 70 pi buffer RDD) was pipetted directly onto the 
RNeasy silica-gel membrane, and incubated at room temperature for 15 minutes. Three hundred- 
fifty microliters of Buffer RW1 were then added to the RNeasy mini column, which was 
centrifuged at room temperature for 15 seconds at 8000 x g. The RNeasy column was transferred 
to a new 2 ml collection tube, and 500 pi of Buffer RPE was added to the column. The tube was 
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closed and centrifuged for 15 seconds at 8000 x g, and the flow-through discarded. Another 500 
pi of Buffer RPE was then added to the tube and centrifuged for 2 minutes at 8000 x g to dry the 
RNeasy silica-gel membrane. The RNease mini column was then carefully removed from the 
collection tube and placed into new 1.5 ml collection tube which was centrifuged for an 
additional to 2 minutes at 8000 x g to ensure that there was no residual flow-thorough. This 
column was placed into a new 1.5 ml collection tube, and 50 pi of RNase-free water was pipetted 
directly onto the RNeasy silica-gel membrane. The tube was closed and centrifuged for 1 minute 
at 8000 x g. The RNeasy column was then discarded and the 1.5 ml microfuge tube containing 
the flow-through with isolated RNA was stored at -80 °C. 
7. Reverse Transcription of RNA 
RNA concentrations were determined by mixing 5 pi of isolated RNA with 95 pi of water 
and measuring the absorbance of the resultant mixture using a Spectromic BioMate 3 
spectrophotometer at a wavelength of 260 nm. An 11 pi aliquot of RNA was then prepared at a 
concentration of 1 pg/11 pi in a 1.5 pi microfuge tube. For each reverse transcription reaction, I 
pi of Promega olgio(dT)15 primer was added to the 11 pi aliquot and incubated at 70°C for 10 
minutes. The mixture was then placed on ice, microfuged at 8000 x g for 20 seconds, and 
returned to ice. A reverse transcriptase mastermix containing 4 pi of 5X first strand synthesis 
buffer (Gibco) per reaction, 2 pi of 0.1 M DTT (Gibco) per reaction, and 1 pi of lOmM dNTPs 
(Gibco) per reaction was then prepared, and 7 pi of the mastermix was added to the microfuge 
tube containing the RNA and oligo(dT) I5 primer. This reaction mixture was incubated at 42 °C 
for 2 minutes, after which 1 pi of Superscript II (Gibco) was added. This was then incubated at 
42 °C for 50 minutes, followed by incubation at 70 °C for 15 minutes. RNase H (0.6 pi, Gibco) 
was then added and the mixture was incubated at 37 °C for 20 minutes. The total volume of the 
reaction was then brought to 100 pi by the addition of 79 pi of water and heated to 100 °C for 10 
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minutes. Immediately afterward, the reaction mixture, which contained reverse transcribed 
cDNA, was placed at -80 °C for storage. 
8. Real-Time Analysis of cDNA 
UCP2 mRNA expression levels were determined using quantitative real time RT-PCR 
amplification with Taqman probes. The primer and probe sequences used for the analysis are as 
follows: UCP2 forward primer CTACAAGACCATTGCCCGAGA; UCP2 reverse primer 
TGTTGCTCGTAATGCCATTGT; UCP2 probe HEX-TGGGAGAGGTCCTTTCCAGAGGCC. 
A standard curve was produced from pooled normal control mRNAs. Reactions were performed 
using lx Taqman master mix (ABI), 200nmoles of each primer, lOOnmoles of the probe, and 
2.5pl of the mRNA reverse-transcription product (cDNA) in a total volume of 25pl. The mRNA 
expression levels of glyceraldehydes 3-phosphate dehydrogenase (GAPDH) were measured using 
TaqMan Pre-developed Human GAPDH Assay Reagents (Applied Biosystems part #4333764F) 
containing both primers and probe for human GAPDH according to the manufacturer’s 
instructions. For each sequence amplified, triplicates of no template control and standard curve 
samples were amplified at the same time for quality control. 
Reactions were run on an MJ Research DNA Engine Opticon 2 continuous fluorescence 
detector real time instrument according to the following thermocycle protocol: 1. 50°C for two 
minutes; 2. 95 °C for ten minutes; 3. 95 °C for fifteen seconds; 4. 58 °C for one minute; 5. read 
plate and repeat the process starting at step 3 fifty more times. The threshold cycle (Ct) values of 
the triplicate samples were checked to ensure that they were within 1 Ct of each other. 
Data obtained from the real time quantitative PCR was analyzed using the 2"aaCt method 
as developed by Livak and Schmittgen (87) and recommended by the manufacturer (Qiagen). 
The 2'aaCt method allows for the relative quantification of the expression level of the target gene 
(UCP2) in a certain population relative to a reference group. Using this method, the data are 
presented as the fold change in gene expression normalized to an endogenous reference gene 
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(GAPDH) and relative to a control group. For the control group, AACT equals zero and 2° equal 
one, so that the fold change in gene expression relative to the control equals one, by definition. 
For the non-control groups, evaluation of 2'AAtT indicates the fold change in gene expression 
relative to the control group. 
In our analysis, we choose several different reference groups, and compared changes in 
UCP2 expression using this technique. For example, in looking at the correlation between UCP2 
expression and coronary artery disease, patients with no to mild coronary disease (the lowest 
tertile of patients with stenosis score 0-10) were chosen as the reference group. Using the 2'AACT 
method thus allowed for relative quantification of UCP2 expression in patients with moderate 
coronary disease (middle tertile of patients, stenosis score 11-25) and severe disease (highest 
tertile, stenosis score>25) as a fold change when compared to the UCP2 levels in the control 
group. In analyzing the correlation between changes in UCP2 expression and body mass index 
(BMI), patients with a normal BMI (18.5-24.9) where chosen as the control group, thus allowing 
for the relative quantification of UCP2 expression in overweight (BMI 25-29.9) and obese (BMI 
>30) patients as compared to the control group. In analyzing the correlation between changes in 
UCP2 expression and the presence of diabetes, diabetics patients were identified either by an 
established diagnosis of diabetes in the medical record, the use of antidiabetic agents or a fasting 
plasma glucose concentration >125 mg/dl. 
10. Statistical Analysis 
All patient data were entered into a database (Filemaker Pro) for further analysis. Results 
are reported as the mean ± standard error of the mean, or number (%) of patients. Differences 
between continuous variables were assessed by Student’s t-test, for categorical variables a chi- 
square analysis was used. A p value <0.05 was considered statistically significant. 
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RESULTS 
Patient Population Results 
A total of 103 qualified patients were entered into the study, mRNA was successfully 
isolated and reverse transcribed into cDNA for real-time analysis, and coronary angiograms were 
reviewed. Relevant demographic and clinical data were collected (Table 1). This population 
consisted of 72 (70%) men and 31 (30%) women, and the mean age of the patients was 
approximately 67 years (age range: 32-86 years). The population was 90% Caucasian with one 
Asian, three Hispanic, and seven African American patients. Twenty-two percent of patients 
were current smokers, 42% had a family history of heart disease, and 67% had a history of 
hypercholesterolemia (defined by a fasting total cholesterol >200 mg/dl or currently on lipid 
lowering therapy). The average body mass index (BMI) was 29.6 kg/m2, and by breakdown, 20% 
of the patients were classified as having a normal weight (BMI <25), 48% as being overweight 
(BMI 25-30), and 32% as being obese (BMI >30), based on World Health Organization criteria. 
Table 1: Demographic and Clinical Characteristics 
Overall Low stenosis score High stenosis score 
(n=103) (n=31) (n=35) 
Age (y) 66.7±12.3 58.6±11.4 70.3±11.4 
Male (%) 70% 42% 91%* 
Body mass index (kg/m2) 29.6±7.6 32.4±10.7 28.2±4.6 
Diabetic (%) 33% 26% 43% 
Hypertensive (%) 65% 61% 71% 
Tobacco use (%) 22% 13% 26% 
Hypercholesterolemic (%) 67% 58% 71% 
Family history (%) 42% 42% 49% 
Values reported as the mean±standard deviation or %. *p<0.005. 
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Generation of Stenosis Score 
The stenosis scores for patients were calculated based on the sum of the atherosclerotic 
disease severity scores for 15 distinct segments of the coronary arteries (86) (See Appendix 2 for 
sample stenosis scoring sheet). The scores for our patient population ranged from zero (figure 
3A) to 60 (figure 3B). 
A 
Figure 3. Sample Coronary Angiograms. 
A. Representative angiograms of the coronary arteries from a patient with no disease (control 
group). Right coronary system (top left panel) and left coronary system (top right panel). 
B. Representative angiogram of the coronary arteries from a patient with multiple, severe 
stenoses of the coronary arteries (severe disease group). Right coronary system (bottom left 
panel) and left coronary system (bottom right panel). 
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Distribution of Stenosis Scores 
The distribution of stenosis scores in our patient population (figure 4) showed a skewing 
towards patients with lower stenosis scores. Scores ranged from zero to sixty, with a mean of 20, 
a median of 18, and a mode of 0. This skewing is likely due the population referred for 
diagnostic cardiac catheterization based on the results of previous stress testing. 
Stenosis Score 
Figure 4. Distribution of Stenosis Scores in the Study Population. 
Amongst the 103 patients enrolled in our study there was a skewing towards lower stenosis 
scores. The mean stenosis score was 20. 
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Validation of the 2'aact Method Using GAPDH as the Endogenous Reference Gene 
To assess the validity of the 2'aact method as a means to determine the relative 
quantification of UCP2 gene expression, varying amounts of cDNA were subjected to RT-PCR 
and a standard curve for the resultant GAPDH Ct was generated and compared to a standard 
curve for UCP2 CT. In order to use GAPDH as our reference gene, it was necessary to confirm 
that the amplification efficiencies of UCP2 (target gene) and GAPDH (reference gene) were 
similar, thus controlling for RNA input amount. The PCR efficiencies for GAPDH and UCP2 
were similar with an efficiency slope for GAPDH of -3.63 and for UCP2 -3.70 (figure 5), thus 
validating the use of GAPDH as our endogenous reference gene for determining relative UCP2 
expression levels using the 2'aact method. 
Figure 5. Quantitative Detection of UCP2 and GAPDH mRNA by Real Time PCR. 
Data represents output Ct values versus total input RNA amount. GAPDH and UCP2 show 
similar real-time PCR reaction efficiencies as determined by the slopes of the lines. 
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Relationship Between Monocyte UCP2 Expression and Atherosclerotic Disease 
Based on their angiographic stensosis score, patients were categorized as having either 
no-to-mild coronary atherosclerotic disease (stenosis score 0-10, n=3 1), moderate disease 
(stenosis score 11-24, n=37), or severe coronary disease (stenosis score > 25, n=35). Real-time 
PCR analysis of patient samples was then performed using the 2'aact method, and changes in the 
expression of the target gene UCP2 were normalized to GAPDH. There was no difference seen 
between mean UCP2 expression levels in monocytes from the control group (no to mild coronary 
disease) and the moderate disease group. However, there was a 35% decrease in mean UCP2 
expression in the patients in the severe group when compared to the no to mild coronary disease 
group (p<0.02, figure 6). These findings indicate that there is a relationship between monocyte 
expression of UCP2 and the atherosclerotic burden of the coronary arteries. 
No to Mild 
n= 31 
Moderate 
n= 37 
Severe 
n= 35 
Figure 6. Correlation of UCP2 Expression and Coronary Artery Disease. 
Average relative UCP2 expression values of patients divided into tertiles based on coronary 
artery atherosclerotic disease burdern. First tertile, no to mild stenosis (stenosis score 0-10); 
second tertitle moderate stenosis (stenosis score 11-24); and third tertile, severe stenosis (stenosis 
score >25). Patients with more severe atherosclerotic disease were found to have a 35% 
(p< 0.02) reduction in their UCP2 mRNA expression levels. 
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Relationship Between Monocyte UCP2 Expression and Body Mass Index 
Previous studies have demonstrated that polymorphisms within the promoter region of 
UCP2 and UCP3 lead to increased mRNA expression in skeletal muscle and are associated with 
changes in body mass (82, 88, 89). Therefore, we examined whether there is also an association 
between monocyte UCP2 expression and obesity. Patients were categorized into three groups 
based on their BMI: normal weight (BMI 18.5-24.9, n=20), overweight (BMI 25-30, n=49), or 
obese (BMI > 30, n=30). In our analysis of the relationship between BMI and UCP2 expression, 
although there was a trend toward an increase in monocyte UCP2 expression with increasing 
BMI, the difference was not statistically significant (figure 7). 
Normal Overweight Obese 
n= 20 n= 49 n= 30 
Figure 7. Correlation of UCP2 Expression and Body Mass Index. 
Average relative monocyte UCP2 expression values in patients categorized as being of normal 
weight (BMI 18.5-24.9), overweight (BMI 25-30), or obese (BMI >30). There was no significant 
difference observed between the three subsets. 
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Relationship Between Monocyte UCP2 Expression and Diabetes 
Previous studies have demonstrated that polymorphisms within the promoter region of 
UCP2 are associated with a decreased risk of diabetes (89, 90). Therefore, we compared UCP2 
gene expression between nondiabetic patients (n=69) and those with diabetes mellitus (n=34). In 
our analysis of the relationship between the incidence of diabetes and monocyte UCP2 
expression, we found no significant difference between the two groups (figure 8). 
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Figure 8. Correlation of UCP2 Expression and Diabetes. 
Average relative UCP2 expression values of non-diabetic and diabetic patients. There was not a 
statistically significant difference observed between the two groups. 
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DISCUSSION 
This work represents the first known study undertaken to examine the relationship 
between uncoupling protein expression and atherosclerotic disease burden in patients. While 
previous work examining the proposed functions of UCPs has indicated that these proteins may 
influence atheromatous plaque formation and progression as a result of their regulation of 
reactive oxygen species production, our findings in this study are the first to demonstrate in a 
clinical setting that decreased monocyte UCP2 expression is associated with the presence of 
severe coronary artery disease in humans. This finding represents an important advancement in 
our understanding in the pathophysiology of atherosclerotic disease. By identifying UCP2 as a 
potential regulator of atherogenesis, there exists not only the possibility that UCP2 gene 
expression analysis could be used as a marker for risk stratification, but also that pharmacologic 
or genetic manipulation of UCP2 expression might help to inhibit atherogenesis. 
The mechanism by which decreased UCP2 expression promotes atherosclerosis is likely 
related to the influence that uncoupling proteins have in the regulation of reactive oxygen species 
production (74, 79, 91). Reactive oxygen species have been hypothesized to play an important 
role in the oxidation of native-LDL into its atherogenic form, and also have been shown to inhibit 
the adhesion of monocytes to the endothelium and transendothelial migration (70, 85, 92, 93). 
The importance of monocyte migration and adhesion to the endothelium lining the coronary 
vessels is recognized as a critical step in atherosclerotic plaque formation, and disruption of this 
process could inhibit plaque formation under otherwise atherogenic conditions. Furthermore, the 
oxidative modification theory of atherogenesis suggests that the oxidation of native-LDL results 
in chemical alterations which make the LDL molecule susceptible to uptake by macrophages, 
thus promoting formation of the “fatty streak” and allowing for the propagation of the 
atherosclerotic plaque. By limiting this process through creating an environment with decreased 
oxidant stress, UCP2 could further prevent the development of severe coronary artery disease. 
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A critical aspect of this study is that we examined UCP2 mRNA expression not from 
coronary endothelium, but rather from isolated peripheral blood mononuclear cells. The rationale 
for this stems from the work by Blanc et al. who demonstrated that the extent and severity of 
atherosclerotic plaque formation in irradiated LDLR-/- mice differs depending on whether they 
received a bone marrow transplant from wild type or UCP2-/- mouse (84). Since irradiated mice 
who received bone marrow from UCP2-/- mice developed more severe atherosclerotic disease as 
compared to mice who received wild-type marrow, it can be concluded that differences in 
circulating cells, generated by the transplanted marrow, are in part responsible for this difference 
in disease progression. One limitation of our experiment with respect to the role of circulating 
monocytes, is that we isolated all of the peripheral mononuclear cells (including lymphocytes) 
from the blood. We chose this approach in part because monocyte-specific isolation is 
significantly more difficult, involving flow cytometric isolation based on cell surface markers, 
and would not haven been feasible for such a large patient sample size, and also because it is 
known that lymphocytes play a critical role in the inflammatory mechanisms of atherosclerosis, 
and thus their level of UCP2 might also be an important factor. However, if a more practical 
method for monocyte isolation were to become available, it would be worthwhile to broaden this 
study by investigating the expression level of UCP2 in isolated monocytes and isolated 
lymphocytes. 
While we did not investigate UCP2 mRNA expression in the coronary endothelium due 
to the invasive and difficult nature of isolating such samples, future studies determining the role 
of endothelial UCPs in protection against oxidant stress are of significant interest. The potential 
for UCP2 to alter monocyte adhesion and transendothelial migration secondary to reduced ROS 
and H202-induced ROS production, suggests that UCP2 expression in endothelial cells might also 
play a role in protection against atherogenesis. Future work to investigate this possibility would 
likely be limited initially to animal models, but would provide further insight into the physiologic 
function of uncoupling proteins in the vascular system. 
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Our data examining the relationship between UCP2 expression, obesity, and diabetes 
failed to reveal a significant relationship. Other studies, however, have identified polymorphisms 
in the promoter of the human UCP2 gene that are associated with changes in insulin secretion, the 
risk of diabetes, and obesity (88-90, 94). These studies focused on the -866G/A polymorphism in 
the promoter region of the UCP2 gene and demonstrate that the A/A polymorphism results in 
increased UCP2 mRNA expression in skeletal muscle and is associated with a decreased risk of 
obesity but increased susceptibility to diabetes. One explanation for why we were unable to 
observe such a correlation between UCP2 expression, obesity, and diabetes, is that our study 
group does not represent the generation population, but rather a small subgroup of patients with 
symptomatic coronary artery disease. Additionally, despite the high frequency (47%) of the A/A 
polymorphism, previous studies have demonstrated this polymorphism accounts for only 15% of 
the risk for obesity (88). Furthermore, those studies measured skeletal muscle UCP2 mRNA 
expression, which is likely regulated by different transcription factors than those in monocytes. 
Future studies involving our patient cohort are planned to identify the patients who have the A/A 
polymorphism, and to compare the frequency of obesity and diabetes, in addition to the severity 
of atherosclerosis, with the frequency of the genotypes (G/G, G/A and A/A) in those subjects. 
Another limitation of this work is that we are only measuring moncyte UCP2 mRNA 
expression at a single point in time. Since the majority of patients who were enrolled in this 
study were older and were undergoing coronary angiography for clinical indications, we were not 
able to investigate the possibility that the monocyte UCP2 expression might have been different 
during the early stages of atherogenesis when levels of LDL oxidation may be crucial to the 
initiation and early progression of the disease. Similarly, one cannot exclude the possibility that 
the decreased UCP2 expression we observe here is not the cause, but rather the result of severe 
coronary disease. While this is unlikely, one method of investigating this possibility would be to 
conduct a prospective study looking at the development of coronary disease in a large cohort of 
patients to determine whether UCP2 expression levels measured in asymptomatic patients is 
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predictive of the severity of the coronary artery disease that develops later. Another approach 
that could be taken to determine the cause and effect relationship between UCP2 expression and 
coronary disease would be to determine UCP2 expression in the offspring of affected patients 
who have low levels of UCP2 expression to study the heritability of UCP2 expression levels. 
Decreased UCP2 expression in pre-symptomatic offspring of individuals with low levels of UCP2 
expression would support the notion that decreased UCP2 levels are not a consequence of 
atherosclerotic disease. 
As previously suggested, the hypothesis that decreased monocyte UCP2 expression plays 
a role in the development of atherosclerotic disease raises the possibility that we might be able to 
alter this prevalent process through pharmacologic or genetic manipulation of UCP2 expression. 
If the oxidation of LDL by reactive oxygen species (generated as a by-product of electron flow 
though the mitochondrial electron transport chain) is a critical step in the initiation and 
progression of atherosclerotic disease, as has been suggested, then increasing UCP2 expression 
would likely decrease the production of these ROS and thus protect again disease development. 
While gene therapies for diseases such as cystic fibrosis have been slow to develop, the reason for 
this stems from the fact that the cells in which you are trying to alter expression are exceedingly 
difficult to manipulate for a variety of reasons. In cystic fibrosis, the respiratory epithelium is the 
affected cell type, but since part of its inherent function is to keep foreign particles, including 
gene transfer vectors, out of the lungs, gene therapy has been very difficult. In contrast, genetic 
manipulation of peripherally circulating mononuclear cells is much easier to achieve, thus 
allowing for the possibility of UCP2 alterations. 
Additionally, by needing to only be distributed in the peripheral blood, there would exist 
the opportunity to develop pharmacologic agents that could be administered orally and could alter 
the regulation of UCP2 expression. Currently, there are four agents that are known to increase 
UCP2 expression in skeletal muscle and liver: the AMPK activator 5-aminoimidazole- 
carboxyaminde-l-nbofuranoside (AICAR), PPAR-a and PPAR-y agonists, and thyroid hormone 
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(95-99). It remains to be determined whether these agents have any effect on the expression of 
UCP2 in monocytes. 
As with any genetic or pharmacologic modification, the effects of increasing UCP2 
expression would need to be more carefully elucidated before such alterations were made, as the 
result of increased expression could also have negative effects. In particular, since ROS also play 
an important role in the body’s response to infection, severe downregulation of their production 
by over-expression of UCP2 might alter immune function. In fact, targeted gene disruption 
studies have shown that as compared to wild-type mice, UCP2-/- knockout mice are completely 
resistant to Toxoplasma gondii, while such infections are lethal in the wild-type mice (83). 
In summary, we have shown that decreased UCP2 mRNA expression is associated with 
an increased burden of coronary artery disease in humans. This finding opens the door to a new 
area of research for both atherosclerotic disease risk stratification and prevention. With further 
understanding of the function of uncoupling proteins, there exists the potential for better 
prevention and recognition of atherosclerotic disease burden, an advance that could substantially 
improve the ability of physicians to treat this disease which affects so many of our patients. 
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APPENDIX 1: SAMPLE PATIENT INFORMATION SHEET 
Code Last name_First name_MRUN Date 
Age Gender Ht (m) wt (kg) LVEF 
□ M DF 
Race:DAfrican American □ Hispanic □ Asian □ Caucasian □ Native American □ Pacific Islander 
Indication 
□ Acute Ml QCSA nCHF □ USA □ Chest pain/+stress test □ Valvular disease 
Risk Factors 
DM DYes DNo 
HTN DYes DNo 
TOB DYes DNo 
Fam Hx DYes QNo 
Hyperchol DYes QNo 
Prev CAD DYes DNo 
CHF DYes QNo 
Treatment □ No therapy □ Medical therapy □ PTC A/Stent □ CABG 
Restenosis? DYes QNo 
Glucose Creat Tot cho 
ASA 
Meds 
□ Yes □ No 
Statin □ Yes □ No 
Niacin □ Yes □ No 
Fibrate □ Yes □ No 
B-blocker □ Yes □ No 
CCB □ Yes □ No 
ACE-I □ Yes □ No 
ARB □ Yes □ No 
Plavix □ Yes □ No 
Insulin □ Yes □ No 
TZD □ Yes □ No 
Metformin □ Yes □ No 
Sulfonylureas □ Yes □ No 
Heparin □ Yes □ No 
GP llbllla □ Yes □ No 
HDL LDL TGLY 
WBC HGB PLT 
Other drugs: 
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APPENDIX 2: SAMPLE STENOSIS SCORING SHEET 
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